Clin Psychopharmacol Neurosci.
2021 May;19(2):181-189. 10.9758/cpn.2021.19.2.181.
Apathy: Neurobiology, Assessment and Treatment
- Affiliations
-
- 1Department of Psychiatry, University of Connecticut, School of Medicine, Farmington, CT, USA
- KMID: 2516171
- DOI: http://doi.org/10.9758/cpn.2021.19.2.181
Abstract
- Apathy is a highly prevalent, disabling and treatment resistant syndrome. It is defined as a quantitative reduction of goaldirected activity in comparison to the patient’s previous level of in multiple dimensions including behavior/cognition, emotion and social interaction. It has been described in major depressive disorder, Alzheimer’s disease, frontotemporal dementia, Parkinson’s Disease, cerebrovascular disease, and vascular dementia, among others. This review will address the neuropsychology and associated neurobiological underpinnings of apathy in the above conditions, identify specific methods to assess apathy clinically, and review the literature on managing apathy across these various disorders.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Apathy syndrome in a patient previously treated with selective serotonin reuptake inhibitors for depression
- Apathy : Conceptual Change and Future Direction
- Post-Stroke Apathy and Anxiety
- The Reliability and Validity of the Korean Version of Apathy Evaluation Scale and its Application in Patients with Schizophrenia
- SPM Analysis of Changes in Cerebral Blood Flow in Alzheimer's Disease with Apathy
